Generation of Fas-independent CD4+ cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide

Yuji Tanaka; Tsuyoshi Takahashi; Mie Nieda; Shigeo Masuda; Koichi Kashiwase; Tokiharu Takahashi; Seishi Ogawa; Shigeru Chiba; Takeo Juji; Hisamaru Hirai

doi:10.1016/S0145-2126(01)00119-9

Generation of Fas-independent CD4+ cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide

Yuji Tanaka, Tsuyoshi Takahashi, Mie Nieda, Shigeo Masuda, Koichi Kashiwase, Tokiharu Takahashi, Seishi Ogawa, Shigeru Chiba, Takeo Juji, Hisamaru Hirai

Research output: Contribution to journal › Article › peer-review

Abstract

In the majority of Ph+ALL patients, p190 bcr-abl fusion protein is generated in the Philadelphia chromosome. The fusion protein may serve as a leukemia antigen because it is not expressed in normal cells and hardly in any other malignancy. From a healthy donor, we have established a p190 bcr-abl fusion peptide-specific CD4+ cytotoxic T-cell clone, activation of which depends on HLA-DRB1*1501. This T-cell clone has a strong cytotoxic activity against autologus MoDCs pulsed with e1a2 peptide and its cytotoxicity is not mediated by Fas/Fas ligand or perforin pathway. Success in establishment of the p190 bcr-abl fusion peptide-specific T-cell clone encourages us to develop a new approach to an effective immunotherapy for Ph+ALL. Copyright © 2002 Elsevier Science Ltd.

Original language	English
Pages (from-to)	317-321
Number of pages	4
Journal	Leukemia Research
Volume	26
Issue number	3
DOIs	https://doi.org/10.1016/S0145-2126(01)00119-9
Publication status	Published - 2002

Keywords

CTL
Minor BCR/ABL
Philadelphia chromosome-positive acute lymphoblastic leukemia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0145-2126(01)00119-9

Cite this

@article{9e523be631674689b030199a05841971,

title = "Generation of Fas-independent CD4+ cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide",

abstract = "In the majority of Ph+ALL patients, p190 bcr-abl fusion protein is generated in the Philadelphia chromosome. The fusion protein may serve as a leukemia antigen because it is not expressed in normal cells and hardly in any other malignancy. From a healthy donor, we have established a p190 bcr-abl fusion peptide-specific CD4+ cytotoxic T-cell clone, activation of which depends on HLA-DRB1*1501. This T-cell clone has a strong cytotoxic activity against autologus MoDCs pulsed with e1a2 peptide and its cytotoxicity is not mediated by Fas/Fas ligand or perforin pathway. Success in establishment of the p190 bcr-abl fusion peptide-specific T-cell clone encourages us to develop a new approach to an effective immunotherapy for Ph+ALL. Copyright {\textcopyright} 2002 Elsevier Science Ltd.",

keywords = "CTL, Minor BCR/ABL, Philadelphia chromosome-positive acute lymphoblastic leukemia",

author = "Yuji Tanaka and Tsuyoshi Takahashi and Mie Nieda and Shigeo Masuda and Koichi Kashiwase and Tokiharu Takahashi and Seishi Ogawa and Shigeru Chiba and Takeo Juji and Hisamaru Hirai",

year = "2002",

doi = "10.1016/S0145-2126(01)00119-9",

language = "English",

volume = "26",

pages = "317--321",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Generation of Fas-independent CD4+ cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide

AU - Tanaka, Yuji

AU - Takahashi, Tsuyoshi

AU - Nieda, Mie

AU - Masuda, Shigeo

AU - Kashiwase, Koichi

AU - Takahashi, Tokiharu

AU - Ogawa, Seishi

AU - Chiba, Shigeru

AU - Juji, Takeo

AU - Hirai, Hisamaru

PY - 2002

Y1 - 2002

N2 - In the majority of Ph+ALL patients, p190 bcr-abl fusion protein is generated in the Philadelphia chromosome. The fusion protein may serve as a leukemia antigen because it is not expressed in normal cells and hardly in any other malignancy. From a healthy donor, we have established a p190 bcr-abl fusion peptide-specific CD4+ cytotoxic T-cell clone, activation of which depends on HLA-DRB1*1501. This T-cell clone has a strong cytotoxic activity against autologus MoDCs pulsed with e1a2 peptide and its cytotoxicity is not mediated by Fas/Fas ligand or perforin pathway. Success in establishment of the p190 bcr-abl fusion peptide-specific T-cell clone encourages us to develop a new approach to an effective immunotherapy for Ph+ALL. Copyright © 2002 Elsevier Science Ltd.

AB - In the majority of Ph+ALL patients, p190 bcr-abl fusion protein is generated in the Philadelphia chromosome. The fusion protein may serve as a leukemia antigen because it is not expressed in normal cells and hardly in any other malignancy. From a healthy donor, we have established a p190 bcr-abl fusion peptide-specific CD4+ cytotoxic T-cell clone, activation of which depends on HLA-DRB1*1501. This T-cell clone has a strong cytotoxic activity against autologus MoDCs pulsed with e1a2 peptide and its cytotoxicity is not mediated by Fas/Fas ligand or perforin pathway. Success in establishment of the p190 bcr-abl fusion peptide-specific T-cell clone encourages us to develop a new approach to an effective immunotherapy for Ph+ALL. Copyright © 2002 Elsevier Science Ltd.

KW - CTL

KW - Minor BCR/ABL

KW - Philadelphia chromosome-positive acute lymphoblastic leukemia

U2 - 10.1016/S0145-2126(01)00119-9

DO - 10.1016/S0145-2126(01)00119-9

M3 - Article

C2 - 11792422

SN - 0145-2126

VL - 26

SP - 317

EP - 321

JO - Leukemia Research

JF - Leukemia Research

IS - 3

ER -

Generation of Fas-independent CD4+ cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this